Table of Content

Part 1. Introduction
1.1 Market Definition
1.2 Key Benefit
1.3 Market Segment
Part 2. Methodology
2.1 Primary
2.2 Secondary
Part 3. Executive Summary

Part 4. Market Overview
4.1 Introduction
4.2 Market Size and Forecast
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.4 Impact of COVID-19 Pandemic

Part 5. Global Market for Uveitis Treatment by Drug Class
5.1 Anti-Inflammatory
5.1.1 Market Size and Forecast
5.2 Antimicrobial Drugs
5.2.1 Market Size and Forecast
5.3 Immunotherapy & Targeted Therapies
5.3.1 Market Size and Forecast
5.4 Others
5.4.1 Market Size and Forecast

Part 6. Global Market for Uveitis Treatment by Disease Type
6.1 Anterior Uveitis
6.1.1 Market Size and Forecast
6.2 Intermediate Uveitis
6.2.1 Market Size and Forecast
6.3 Panuveitis
6.3.1 Market Size and Forecast
6.4 Posterior Uveitis
6.4.1 Market Size and Forecast
6.5 Others
6.5.1 Market Size and Forecast

Part 7. Global Market for Uveitis Treatment by Distribution Channel
7.1 Drug Stores And Retail Pharmacies
7.1.1 Market Size and Forecast
7.2 Hospital Pharmacies
7.2.1 Market Size and Forecast
7.3 Online
7.3.1 Market Size and Forecast
7.4 Others
7.4.1 Market Size and Forecast

Part 8. Global Market for Uveitis Treatment by Region
8.1 Asia-Pacific
8.1.1 Market Size and Forecast
8.2 Europe
8.2.1 Market Size and Forecast
8.3 North America
8.3.1 Market Size and Forecast
8.4 Middle East And Africa (Mea)
8.4.1 Market Size and Forecast
8.5 South America
8.5.1 Market Size and Forecast

Part 9. Key Competitor Profiles
9.1 Abbvie Inc.
9.2 Actavis plc
9.3 Alimera Sciences, Inc.
9.4 Amgen Inc.
9.5 Bausch Health Companies Inc.
9.6 Clearside Biomedical, Inc.
9.7 Eye Point Pharmaceuticals Securities Corporation
9.8 Mylan N.V.
9.9 Novartis International AG
9.10 Santen Pharmaceutical Co., Ltd.
*LIST IS NOT EXHAUSTIVE

Part 10. Patent Analysis
10.1 Patent Statistics
10.2 Regional Analysis
10.3 Trends Analysis

DISCLAIMER
ABOUT GEN CONSULTING COMPANY